Growth hormone (recombinant somatropin) therapy

The human evidence for somatropin as an anti-ageing intervention is unusually well characterised, and it is not supportive. The definitive synthesis is Liu et al., a systematic review of 31 randomised controlled trials of GH in healthy elderly adults (Annals of Internal Medicine, 2007). It found small body-composition shifts (fat mass down about 2.1 kg, lean body mass up about 2.1 kg) with no demonstrated gain in strength, function, quality of life or survival, and significantly higher rates of soft tissue oedema, arthralgia, carpal tunnel syndrome, gynaecomastia, and new-onset diabetes or impaired fasting glucose. The authors concluded GH cannot be recommended as an antiaging therapy. Nothing since has overturned that: the frequently cited TRIIM trial (Fahy et al., Aging Cell, 2019) reported thymic regrowth and a roughly 1.5 to 2.5 year reduction in epigenetic age, but it enrolled only nine men, had no control arm, and combined rhGH with DHEA and metformin, so no effect can be attributed to GH alone and no clinical outcome was measured. Separately, the benefit in genuinely GH-deficient adults (pituitary disease, hypopituitarism) is real and is the basis of the registered indication, but that population is not the ageing population these clinics are marketing to. There is also a documented harm signal in the other direction: lower GH/IGF-1 signalling is associated with longer life in multiple model organisms and in human GH-receptor-deficiency cohorts, so the mechanistic rationale for supplementing GH to extend healthspan is contested rather than merely unproven. Chronic supraphysiological GH causes acromegaly, insulin resistance, and cardiovascular disease. Even the Singapore clinic pages advertising the treatment state plainly that HGH is not the anti-ageing miracle it is claimed to be.

What it is

Plain-language explainer

Categories

Common questions

What is Growth hormone (recombinant somatropin) therapy?

The human evidence for somatropin as an anti-ageing intervention is unusually well characterised, and it is not supportive. The definitive synthesis is Liu et al., a systematic review of 31 randomised controlled trials of GH in healthy elderly adults (Annals of Internal Medicine, 2007). It found small body-composition shifts (fat mass down about 2.1 kg, lean body mass up about 2.1 kg) with no demonstrated gain in strength, function, quality of life or survival, and significantly higher rates of soft tissue oedema, arthralgia, carpal tunnel syndrome, gynaecomastia, and new-onset diabetes or impaired fasting glucose. The authors concluded GH cannot be recommended as an antiaging therapy. Nothing since has overturned that: the frequently cited TRIIM trial (Fahy et al., Aging Cell, 2019) reported thymic regrowth and a roughly 1.5 to 2.5 year reduction in epigenetic age, but it enrolled only nine men, had no control arm, and combined rhGH with DHEA and metformin, so no effect can be attributed to GH alone and no clinical outcome was measured. Separately, the benefit in genuinely GH-deficient adults (pituitary disease, hypopituitarism) is real and is the basis of the registered indication, but that population is not the ageing population these clinics are marketing to. There is also a documented harm signal in the other direction: lower GH/IGF-1 signalling is associated with longer life in multiple model organisms and in human GH-receptor-deficiency cohorts, so the mechanistic rationale for supplementing GH to extend healthspan is contested rather than merely unproven. Chronic supraphysiological GH causes acromegaly, insulin resistance, and cardiovascular disease. Even the Singapore clinic pages advertising the treatment state plainly that HGH is not the anti-ageing miracle it is claimed to be.

How strong is the evidence for Growth hormone (recombinant somatropin) therapy?

Clinical. There is human trial evidence, which is the strongest grade variis applies to a protocol.

Is Growth hormone (recombinant somatropin) therapy approved in Singapore?

Health Sciences Authority position on record: Somatropin is registered with HSA as a prescription-only therapeutic product in Singapore (registered brands include Norditropin, Saizen and SciTropin A) and is listed on the National Drug Formulary. The registered indications are growth hormone deficiency and conditions causing short stature, plus replacement therapy in adults with GH deficiency associated with hypothalamic or pituitary disease. Any use for age-related decline or general 'anti-ageing' in an adult without diagnosed deficiency is off-label. It is available only on a doctor's prescription; unregistered HGH products sold outside that channel are illegal under HSA regulation. Note: I did not open a specific HSA product register entry, so the brand-level registration detail rests on the National Drug Formulary and HealthHub listings rather than a direct register lookup.. An evidence grade and a regulatory approval are different questions.

Is Growth hormone (recombinant somatropin) therapy approved in Australia?

Therapeutic Goods Administration position on record: Somatropin is TGA-registered in Australia as a Schedule 4 Prescription Only Medicine. Genotropin, for example, is registered for short stature due to decreased or failed pituitary growth hormone secretion, severe adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome and growth disturbance in chronic renal insufficiency. Long-acting analogues have since been registered for paediatric GHD (Skytrofa/lonapegsomatropin was TGA-approved in 2025). PBS subsidy is restricted to childhood-onset or late-onset severe growth hormone deficiency and requires treatment by an endocrinologist. There is no TGA-approved indication for anti-ageing, healthspan, or performance and image enhancement; Australian authorities state that GH and GH-raising peptides are permitted only for legitimate medical purposes on prescription and are not approved for performance or image enhancement. The TGA has issued alerts about unapproved imported somatropin and peptide products.. An evidence grade and a regulatory approval are different questions.

What else is Growth hormone (recombinant somatropin) therapy called?

Also known as HGH, hGH, somatropin, somatotropin, human growth hormone therapy, recombinant human growth hormone, rhGH.